$216.04▾ 0.28%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Biogen Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days4 articles
1 bullish3 neutral0 bearish
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookAutoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape
Hummingbird Bioscience Appoints Dr. James Garner as President
Lilly Builds Neuroscience into a New Long-Term Growth Driver